CalciMedica Stockholders Approve Reverse Split, Equity Plan Expansion, and Warrant Issuance

summarizeSummary

Stockholders approved a reverse split, a 7.5M share equity plan expansion, and warrant issuances covering up to 40.7M shares, giving the Board flexibility to address Nasdaq listing and funding needs.

check_boxKey Events · Corporate Governance and Compliance · CALC

• Reverse Stock Split Approved

  Stockholders approved a reverse split at a ratio between 1-for-2 and 1-for-10, with the Board having discretion on timing and ratio to regain Nasdaq compliance.

• Equity Plan Expanded by 7.5M Shares

  The 2023 Equity Incentive Plan share reserve increased by 7,500,000 shares to a total of 12,333,690 shares, providing more equity for employee compensation.

• Warrant Issuance Approved

  Stockholders approved issuance of Series A and Series B Warrants to purchase up to 18,673,429 shares each (37,346,858 total) under Nasdaq Rule 5635(d), plus 1,680,565 shares each (3,361,130 total) to directors and officers under Rule 5635(c).

• Board Discretion on Reverse Split

  The Board may effect the reverse split at any time and at any ratio within the approved range, providing flexibility to respond to Nasdaq listing requirements.

auto_awesomeAnalysis · CALC · Life Sciences

CalciMedica's stockholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-10, giving the Board discretion to execute it to regain Nasdaq compliance. They also approved a 7.5 million share increase to the equity incentive plan and the issuance of up to 40.7 million shares underlying Series A and Series B warrants from the June private placement. These approvals clear the path for significant potential dilution and provide the Board with tools to address the company's going concern and delisting risk.